DrugPatentWatch Database Preview
Details for Patent: 8,062,652
Which drugs does patent 8,062,652 protect, and when does it expire?
Patent 8,062,652 protects SUPPRELIN LA and is included in one NDA.
This patent has three patent family members in three countries.
Summary for Patent: 8,062,652
| Title: | Compositions and methods for treating precocious puberty |
| Abstract: | The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP). |
| Inventor(s): | Kuzma; Petr (Princeton, NJ) |
| Assignee: | Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA) |
| Application Number: | 11/155,822 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Device; |
Drugs Protected by US Patent 8,062,652
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharm | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | RX | Yes | Yes | Start Trial | Start Trial | METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,062,652
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2570960 | Start Trial | |||
| European Patent Office | 1773293 | Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2006009801 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
